In line with these data, a synergistic effect between anti-CHI3L1 and either anti-PD-1 or anti-cytotoxic T-lymphocyte antigen (CTLA)-4 ICB has recently been described for melanoma lung metastases [39, 40]. Here, CHI3L1 is linked to melanoma.